{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/seborrhoeic-dermatitis/management/seborrhoeic-dermatitis-infants/","result":{"pageContext":{"chapter":{"id":"ca5edad5-d74c-565f-b254-2c59bed62420","slug":"seborrhoeic-dermatitis-infants","fullItemName":"Scenario: Seborrhoeic dermatitis - infants","depth":2,"htmlHeader":"<!-- begin field b30b2700-4def-4863-ae35-20ddfbb940a1 --><h2>Scenario: Seborrhoeic dermatitis - infants</h2><!-- end field b30b2700-4def-4863-ae35-20ddfbb940a1 -->","summary":"Covers what advice to give parents, how to manage seborrhoeic dermatitis in infants, and when to follow up and refer.","htmlStringContent":"<!-- begin item aa905772-8a5a-422a-944a-9dc8ce01e83a --><!-- begin field 1284c798-1897-4b8e-961b-acbc0158da1a --><p>From birth to 12 months.</p><!-- end field 1284c798-1897-4b8e-961b-acbc0158da1a --><!-- end item aa905772-8a5a-422a-944a-9dc8ce01e83a -->","topic":{"id":"b328d01a-a44a-57e1-8920-22321b4c6c8b","topicId":"67c69cb5-e030-443e-802f-758ce0fe90f8","topicName":"Seborrhoeic dermatitis","slug":"seborrhoeic-dermatitis","lastRevised":"Last revised in February 2019","chapters":[{"id":"2c32aabf-f751-57c2-9fb1-bfd7e4c7e58d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96bfb0b4-09f0-5525-aaf3-ca2354a87cb4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9bf8c16e-f128-5c6a-b6e8-d4223dcf2346","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"debcdac6-7ef3-5820-90b8-353614354fc7","slug":"changes","fullItemName":"Changes"},{"id":"32308918-ad23-5b7d-a1c5-7c7a4edf3e35","slug":"update","fullItemName":"Update"}]},{"id":"efc69a37-1a91-539d-b4ce-b1cfc1d48baf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"09ce3910-2aa3-537d-97db-f473bf3f3c99","slug":"goals","fullItemName":"Goals"},{"id":"37776aed-67d4-5001-8e82-0fec56ecaa71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2638b372-65f4-549c-9c2d-fff4cf1c933d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"df03f868-28e0-52a9-9f30-aecfccaa745c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bf290438-2d1b-5233-a43a-e3fe0cbccaab","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d66aeca6-f9ff-5104-94d3-d115d20ad7d1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f9559ed-2d1c-52f3-ae50-cb983d1b7c7c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025302eb-268d-585c-b9a4-d83b4dbb0e5b","slug":"definition","fullItemName":"Definition"},{"id":"43d0a434-92b2-5c53-b4bd-f8ab32a8c0a3","slug":"causes","fullItemName":"Causes"},{"id":"0f04315e-ba03-5be7-a5dc-c724c1e3fe90","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad49e37a-e725-5ad1-9e7b-f84a79627169","slug":"complications","fullItemName":"Complications"},{"id":"50cfb7dd-1ad7-5d22-9c7e-8472fb0af48c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26dec6e1-8806-50b7-869d-1e010fa15e89","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f674962-dade-5ce5-9b92-60820da005f7","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f384b060-7f9e-593e-8a77-6bbf957fd0c4","slug":"assessment","fullItemName":"Assessment"},{"id":"2b98bc5c-ae88-522e-89c4-79e05d301c3f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"521d1a4a-9184-5872-ab66-2a3fed074cc8","fullItemName":"Management","slug":"management","subChapters":[{"id":"ca5edad5-d74c-565f-b254-2c59bed62420","slug":"seborrhoeic-dermatitis-infants","fullItemName":"Scenario: Seborrhoeic dermatitis - infants"},{"id":"4172af9c-8f8b-5bcc-a160-ca83f520099c","slug":"seborrhoeic-dermatitis-scalp-beard","fullItemName":"Scenario: Seborrhoeic dermatitis - scalp and beard"},{"id":"ad81b0ed-2e0c-5a1d-a7a0-e823d40d7ca4","slug":"seborrhoeic-dermatitis-face-body","fullItemName":"Scenario: Seborrhoeic dermatitis - face and body"},{"id":"715da1f8-f458-5eec-96e8-85e22060d505","slug":"seborrhoeic-dermatitis-severe-or-widespread","fullItemName":"Scenario: Seborrhoeic dermatitis - severe or widespread"}]},{"id":"bac53cb4-0b97-5d4b-8ce4-07a9584a5e4f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"970b1e50-a3fc-503d-bbe8-29ecfa575d20","slug":"products-available-otc","fullItemName":"Products available OTC"},{"id":"9b1c8434-e7ce-5cd0-8c49-9e1076fbcecb","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"d35c5c70-d96b-5a9a-a708-2e051cf3cece","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"}]},{"id":"b5cb8438-116a-5790-9b0f-2a480c577056","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"03823e51-3fec-53db-8dde-3fbe6e94526c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"364fda13-808d-599d-84cd-2b31ed7d0d94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fd9a5e23-6ee9-503f-bbc4-7239d8555e0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1120e62a-fd06-536e-8caf-945332e36549","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"214850c4-e7af-5924-9a63-09325facd062","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bfa9b404-d181-55eb-a3b2-8da0ee4edb43","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5171db55-6873-590e-b670-2d66a4b1b1eb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"521d1a4a-9184-5872-ab66-2a3fed074cc8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"13b88310-cf19-5964-b24d-b4c37df5ca9e","slug":"management-of-infantile-seborrhoeic-dermatitis","fullItemName":"Management of infantile seborrhoeic dermatitis","depth":3,"htmlHeader":"<!-- begin field d7e2aeac-5c3d-44ff-9f00-2cdc9ae1c6b9 --><h3>How should I manage an infant with seborrhoeic dermatitis?</h3><!-- end field d7e2aeac-5c3d-44ff-9f00-2cdc9ae1c6b9 -->","summary":null,"htmlStringContent":"<!-- begin item dd628f15-4e76-45de-a8e7-86b0a143f6d7 --><!-- begin field 12a14926-71b8-4dd0-befc-dcf29bfa585e --><ul><li>Reassure the parent/carer that infantile seborrhoeic dermatitis is not a serious condition — it does not usually trouble the infant and typically resolves spontaneously within a few months.<ul><li>Patient information is available from:<ul><li>The British Association of Dermatologists — <a data-hyperlink-id=\"9ac0817b-ff9d-42c0-b07e-a9ff00bb5df7\" href=\"http://www.bad.org.uk/for-the-public/patient-information-leaflets/seborrhoeic-dermatitis\" target=\"_blank\">Seborrhoeic dermatitis</a>.</li><li>The National Eczema Association — <a data-hyperlink-id=\"d37078bc-1d4d-4056-9f61-a9ff00bb6098\" href=\"http://www.eczema.org/infantile-seborrhoeic\" target=\"_blank\">Infantile seborrhoeic dermatitis</a>.</li></ul></li></ul></li><li>If the scalp is affected (the most common presentation):<ul><li>Advise the parent/carer to massage a topical emollient (such as olive or vegetable oil) onto the scalp to loosen scales, brush gently with a soft brush and wash off with shampoo.<ul><li>Thicker scales can be soaked overnight with white petroleum jelly, vegetable or olive oil, and shampooed in the morning.</li></ul></li><li>If this is not effective consider prescribing a topical imidazole cream (clotrimazole 1% or miconazole):<ul><li>Clotrimazole 1% cream: apply 2–3 times daily for up to 4 weeks.</li><li>Miconazole 2% cream: apply twice daily for up to 4 weeks.</li></ul></li><li>If symptoms persist longer than 4 weeks with treatment, seek specialist advice.</li></ul></li><li>If areas other than the scalp are affected (including the nappy area):<ul><li>Advise bathing the infant every day using an emollient as a soap substitute; avoid soaps/detergents and vigorous cleansing.<ul><li>Encourage frequent nappy changes and use of barrier emollients such as Zinc and Castor Oil ointment BP or white soft paraffin BP ointment.</li></ul></li><li>Consider prescribing a topical imidazole (clotrimazole 1% or miconazole) — treat for up to 4 weeks until symptoms resolve.<ul><li>If symptoms persist longer than 4 weeks with treatment, seek specialist advice.</li></ul></li><li>Topical corticosteroids are not usually advised — low potency topical corticosteroids (such as 1% hydrocortisone) may be helpful for some infants with nappy rash.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nappy-rash/\">Nappy rash</a>.</li></ul></li></ul></li><li>Routine follow up is not usually required, however, the parent/carer should be advised to seek review if:<ul><li>Response to treatment is poor.</li><li>Symptoms worsen despite treatment.</li><li>Signs of infection (for example crusting, oozing, and bleeding) develop.</li></ul></li><li>If symptoms recur:<ul><li>Consider repeating a course of treatment if confident that the diagnosis is correct — seek specialist advice if diagnosis is uncertain.</li></ul></li><li>Consider referral to a dermatologist/paediatrician if there is:<ul><li>Severe or widespread seborrhoeic dermatitis — consider possible serious <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/background-information/causes/\">underlying conditions</a> such as immunodeficiency.</li><li>Diagnostic uncertainty.</li><li>Failure to respond to routine treatment.</li></ul></li></ul><!-- end field 12a14926-71b8-4dd0-befc-dcf29bfa585e --><!-- end item dd628f15-4e76-45de-a8e7-86b0a143f6d7 -->","subChapters":[{"id":"bcbba020-ffe5-506c-a1c6-39d0760576ac","slug":"basis-for-recommendation-b4e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ffd91c99-fda6-4690-975c-6ae8c55cec67 --><h4>Basis for recommendation</h4><!-- end field ffd91c99-fda6-4690-975c-6ae8c55cec67 -->","summary":null,"htmlStringContent":"<!-- begin item b4eb8944-47b4-4a56-bf8d-992e13d73f43 --><!-- begin field 5b25e2e8-6b63-47f7-8acd-204b49ed286c --><p>The recommendations on treatment of seborrhoeic dermatitis in infants are based on clinical guidance from the World Health Organisation <em>Evidence and recommendations on seborrhoeic dermatitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>], <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>] and the Primary Care Dermatological Society <em>Seborrhoeic eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>], and expert opinion from the British Association of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>], Rook’s textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BMJ Best Practice, 2018</a>].</p><h5>Simple advice</h5><ul><li>Recommendations on simple measures are based on expert opinion in clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>], a textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BMJ Best Practice, 2018</a>].</li><li>Infantile seborrhoeic dermatitis is usually self-limiting and resolves by four months of age. In some babies it may persist for 8–12 months (or longer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>].</li></ul><h5>Topical preparations</h5><ul><li>CKS has extrapolated recommendations on frequency of application of clotrimazole and miconazole cream from the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BNF 76, 2018</a>] and the manufacturers' Summaries of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">ABPI, 2016b</a>].</li><li>Ketoconazole is not licenced for use in infants [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BNF 76, 2018</a>].</li></ul><h5>Recurrence</h5><ul><li>CKS could find no systematic reviews of the treatment of recurrent episodes of seborrhoeic dermatitis in infants.</li><li>As infantile seborrhoeic dermatitis usually resolves within several weeks to several months, is self-limiting and the course is generally short, CKS does not recommend prophylactic measures, but suggests reviewing the diagnosis if symptoms persist.</li></ul><h5>Review</h5><ul><li>CKS could find no guidelines or evidence on the follow up of seborrhoeic dermatitis in infants, and therefore recommendations are pragmatic based on clinical good practice. </li></ul><h5>Referral</h5><ul><li>The recommendation to refer if there is diagnostic uncertainty or the person is not responding to topical treatment is supported by clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>].</li><li>Generalized seborrhoeic dermatitis is uncommon in otherwise healthy children and usually is associated with immune deficiencies — referral to identify a serious underlying cause is indicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>].</li></ul><!-- end field 5b25e2e8-6b63-47f7-8acd-204b49ed286c --><!-- end item b4eb8944-47b4-4a56-bf8d-992e13d73f43 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}